A phase II randomised, double-blind, placebo-controlled, proof of concept study of oral seletalisib in patients with primary Sjögren’s syndrome (PSS).

0 avis

A phase II randomised, double-blind, placebo-controlled, proof of concept study of oral seletalisib in patients with primary Sjögren’s syndrome (PSS).

Archive ouverte

Edité par CCSD -

International audience

Langue: en

Consulter en ligne

Consulter le document

Suggestions

Du même auteur

A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren’s syndrome

Archive ouverte | Juarez, Maria | CCSD

International audience. This phase 2 proof-of-concept study (NCT02610543) assessed efficacy, safety and effects on salivary gland inflammation of seletalisib, a potent and selective PI3Kδ inhibitor, in patients with...

Phenotype of biopsy-proven patients with primary Sjögren syndrome lacking ro autoantibodies: high frequency of dryness symptoms with low systemic activity (big data Sjögren projct).

Archive ouverte | Retamozo, Soledad | CCSD

International audience

Seletalisib for Activated PI3Kδ Syndromes: Open-Label Phase 1b and Extension Studies

Archive ouverte | Diaz, Nieves | CCSD

International audience

Chargement des enrichissements...